Tuesday, 18 Dec 2018

You are here

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in bone mineral density (BMD) compared to those who received active comparator (risedronate).  This also follows an EU CHMP recommendation last month calling for the approval of denosumab for use in GIOP.

"Patients on long-term systemic glucocorticoid medications can experience a rapid reduction in bone mineral density within a few months of beginning treatment1," said study lead Kenneth F. Saag, M.D., M.Sc., Professor of Medicine at the University of Alabama at Birmingham School of Medicine. "With this approval, patients who receive treatment with glucocorticoids now have a new option to help improve their bone mineral density."

The approval is supported by the 12-month primary analysis of a 24-month Phase 3, randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia 60 mg subcutaneously every six months compared with oral risedronate 5 mg once daily in 795 patients receiving glucocorticoid treatment, greater than or equal to 7.5 mg/day oral prednisone (or equivalent).

The study included two patient groups: a glucocorticoid-initiating subpopulation, receiving treatment for less than three months prior to study enrollment and planning to continue treatment for a total of at least six months, and a glucocorticoid-continuing subpopulation, receiving treatment for greater than or equal to three months prior to study enrollment and planning to continue treatment for a total of at least six months.

Study results showed that in the glucocorticoid-continuing subpopulation, Prolia demonstrated a significantly greater increase in lumbar spine BMD compared to risedronate at one year (3.8 percent versus 0.8 percent, respectively) with a treatment difference of 2.9 percent (p<0.001). Similarly, in the glucocorticoid-initiating subpopulation, denosumab demonstrated a significantly greater increase in lumbar spine BMD compared to risedronate at one year (4.4 percent versus 2.3 percent, respectively) with a treatment difference of 2.2 percent (p<0.001). Consistent effects on lumbar spine BMD were observed regardless of gender; race; geographic region; menopausal status; and baseline age, lumbar spine BMD T-score, and glucocorticoid dose within each subpopulation.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage

Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of OA, they reduced cartilage degeneration.

Low Risk of Serious Complications with Meniscectomy

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days. They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Pre-Diabetes Associated Risk for Arthritis, Obesity and Physical Inactivity

The current MMWR reports that arthritis is seen in nearly one-third of adults with prediabetes and that more than half of such patients are obese and not engaged in regular physical activity.

Doctor-diagnosed arthritis affects 54.4 million in the U.S. and the CDC expects this to rise to 78.4 million by 2040.

Controversial New Super Opioid Approved by FDA

Amidst a new DEA report demonstrating a record number of opioid overdose deaths (n-72,000 or ~ 200 deaths per day), the FDA has approved a newer and far more potent opioid than those that are currently being abused at alarming rates. The new agent is named Dsuvia.

Late Breaker: Can Tanezumab Be Revived for OA?

The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology in Chicago last week.